The tablet is a targeted prescription-based therapy that belongs to the medications known as kinase inhibitors. Ponatinib tablet uses are some of certain types of Philadelphia chromosome-positive leukemia, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). It works by blocking the function of abnormal tyrosine kinase and stopping cancer growth.